Table 1. Characteristics of randomized clinical trials included in the systematic review about comparison of repetitive transcranial magnetic stimulation (rTMS) and control conditions for post-stroke depression.
| Study (year, country, ref.) | Depression (diagnosed criteria) | Mean age±SD (years) | rTMS group | Control group | Duration | Outcome measured |
|---|---|---|---|---|---|---|
| Chen et al. (2005) China (18) | CCMD-2R | 61.3±4.7 | Bilateral-rTMS+Routine treatment | Routine treatment | 1w | HAMD, mSSS, Remission |
| Du et al. (2005) China (19) | HAMD-17>8 | 57.6±10.8 | Bilateral-rTMS+Fluoxetine+Routine treatment | Fluoxetine+Routine treatment | 4w | HAMD, MMSE |
| Gu and Chang (2017) Korea (20) | BDI>12 and HAMD-17>6 | 60.8±9.1 | Unilateral-rTMS | Sham stimulation | 2w | HAMD, MBC |
| Jorge et al. (2003) USA (7) | DSM-IV | 64.8±10.2 | Unilateral-rTMS | Sham stimulation | 3w | HAMD, Remission |
| Jorge et al. (2008) USA (25) | DSM-IV | 63.7±8.9 | Unilateral-rTMS | Sham stimulation | 3w | HAMD, Remission |
| Narushima et al. (2010) USA (26) | DSM-IV | 62.8±8.5 | Unilateral-rTMS | Sham stimulation | 3w | HAMD, MMSE, Remission |
| Yan et al. (2010) China (27) | CCMD-3R | 68.6±7.9 | Unilateral-rTMS+Deanxit (left DLPFC, 10Hz,110%RMT)/(right DLPFC,1Hz, 110%RMT) | Sham stimulation+Deanxit | 1w | HAMD, NIHSS |
CCMD: Chinese Classification and Diagnosis of Mental Diseases; HAMD: Hamilton Depression Scale; BDI: Beck Depression Inventory; DSM: Diagnostic and Statistical Manual of Mental Disorders; DLPFC: dorsolateral prefrontal cortex; Deanxit: Flupentixol and Melitracen tablets; mSSS: modified Scandinavian Stroke Scale; MMSE, Mini-Mental State Examination; MBC: modified Brunnstrom Classification; NIHSS: National Institutes of Health Stroke Scale.